Forte Biosciences
Open
$17.18
Prev. Close
$17.18
High
$17.23
Low
$17.09
Market Snapshot
$238.14M
-3.1
-12.17
22
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The company is headquartered in Dallas, Texas and currently employs 19 full-time employees. The company went IPO on 2017-04-13. The company is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The firm's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The company is headquartered in Dallas, Texas and currently employs 19 full-time employees. The company went IPO on 2017-04-13. The company is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The firm's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Recently from Cashu
Forte Biosciences Develops Innovative Treatments for Pediatric Skin Disorders
Forte Biosciences Advances Therapeutic Solutions for Pediatric Skin Disorders Forte Biosciences is at the forefront of developing innovative therapies aimed at addressing pediatric skin disorders, par…
Forte Biosciences R&D Day: Innovations in Autoimmune Treatments and FB102 Unveiling
Forte Biosciences Gears Up for R&D Day Focused on Innovative Autoimmune Treatments Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, announces an R&D Day scheduled for December 3, 2…
Forte Biosciences Hosts R&D Day to Highlight Innovative Autoimmune Therapy FB102
Forte Biosciences Prepares for R&D Day to Showcase Innovative Autoimmune Therapy Forte Biosciences, Inc. is set to host an R&D Day on December 3, 2024, at 4:30 p.m. ET, focusing on the promising devel…
Forte Biosciences (FBRX) Advances FB102 Clinical Trials for Celiac Disease Treatment
Forte Biosciences Advances Clinical Trials for Autoimmune Treatment Forte Biosciences, Inc. (NASDAQ: FBRX) focuses on autoimmune and autoimmune-related diseases, revealing notable progress in its clin…